ERBB2 and breast carcinoma: Collectively, our data demonstrated that concomitant expression of the miRNA cluster targeting of erbB3 significantly inhibited proliferation of HER2-overexpressing breast cancer cells, likely via cell cycle G1 arrest as well as inactivation of the HER3 signaling pathways.